Site Maintenance will take place from 4:00 PM on 2024-04-29 to 9:00 AM on 2024-05-01.
Please do not make any content change during this time, otherwise all the changes will be lost.

Select Publications

Preprints

Moreno C; Castanheira F; Stella AO; Chung F; Aggarwal A; Cole A; Loo L; Dupuy A; Kong Y; Hagimola L; Fenwick J; Coleman P; Willson M; Bui-Marinos M; Hesselson D; Gamble J; Passam F; Turville S; Kubes P; Neely G, 2023, P-Selectin promotes SARS-CoV-2 interactions with platelets and the endothelium, , http://dx.doi.org/10.1101/2023.02.13.528235

Aggarwal A; Stella A; Akerman A; Walker G; Milogiannakis V; McAllery S; Esneau C; Silva MR; Lu Y; Forster C; Hal SV; Mathivanan V; Fitcher C; Hoppe AC; Munier ML; Darley D; Matthews G; Starck D; Robosa R; Bartlett N; Rawlinson W; Kelleher A; Turville S, 2022, Rapid isolation and resolution immune evasion and viral fitness across contemporary SARS-CoV-2 variants, , http://dx.doi.org/10.21203/rs.3.rs-1210846/v1

Loo L; Waller M; Cole A; Stella A; Moreno C; Denes C; Hamoudi Z; Chung F; Aggarwal A; Low J; Patel K; Siddiquee R; Mackay J; Turville S; Hesselson D; Neely G, 2022, LRRC15 suppresses SARS-CoV-2 infection and controls collagen production, , http://dx.doi.org/10.21203/rs.3.rs-1172665/v1

Li L; Honda-Okubo Y; Huang Y; Jang H; Carlock MA; Baldwin J; Piplani S; Bebin-Blackwell AG; Forgacs D; Sakamoto K; Stella A; Turville S; Chataway T; Colella A; Triccas J; Ross TM; Petrovsky N, 2021, Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection, , http://dx.doi.org/10.1101/2021.07.03.451026

Garcia-Valtanen P; Hope C; Masavuli M; Lip Yeow AE; Balachandran H; Mekonnen Z; Al-Delfi Z; Abayasingam A; Agapiou D; Stella AO; Aggarwal A; Gummow J; Ferguson C; O’Connor S; McCartney E; Lynn D; Maddern G; Gowans E; Reddi BAJ; Shaw D; Kok-Lim C; Turville S; Beard M; Weiskopf D; Sette A; Bull R; Barry S; Grubor-Bauk B, 2021, COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection, , http://dx.doi.org/10.1101/2021.11.08.21266035

Loo L; Waller M; Moreno C; Cole A; Stella AO; Pop O-T; Jochum A-K; Ali OH; Denes C; Denes C; Hamoudi Z; Chung F; Aggarwal A; Low J; Patel K; Siddiquee R; Kang T; Mathivanan S; Mackay J; Flatz L; Hesselson D; Turville S; Neely G, 2021, Fibroblast-expressed LRRC15 suppresses SARS-CoV-2 infection and controls antiviral and antifibrotic transcriptional programs, , http://dx.doi.org/10.1101/2021.11.09.467981

Counoupas C; Pino P; Stella A; Ashley C; Lukeman H; Bhattacharyya N; Tada T; Anchisi S; Metayer C; Martinis J; Aggarwal A; Dcosta B; Kint J; Wurm M; Landau N; Steain M; Turville S; Wurm F; David S; Triccas J, 2021, Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens, , http://dx.doi.org/10.1101/2021.08.18.456891

Aggarwal A; Stella AO; Walker G; Akerman A; Milogiannakis V; Brilot F; Amatayakul-Chantler S; Roth N; Coppola G; Schofield P; Jackson J; Henry J; Mazigi O; Langley D; Lu Y; Forster C; McAllery S; Mathivanan V; Fichter C; Hoppe AC; Munier ML; Jack H-M; Cromer D; Darley D; Matthews G; Christ D; Khoury D; Davenport M; Rawlinson W; Kelleher A; Turville S, 2021, SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, , http://dx.doi.org/10.1101/2021.12.14.21267772

Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson S; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer D; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA, Maintenance of Broad Neutralising Antibodies and Memory B Cells 12 Months Post-Infection Is Predicted by SARS-CoV-2 Specific CD4+ T Cell Responses, , http://dx.doi.org/10.2139/ssrn.3920641


Back to profile page